Almirall Celebrates Major Milestone in Regulatory Approval
Almirall, S.A. (ALM), a prominent global pharmaceutical company focused on medical dermatology, has proudly announced that it has completed the decentralized regulatory procedure for efinaconazole in Europe. This triazole antifungal compound is specifically designed to treat onychomycosis, a nail fungal infection, marketed under the name Jublia.
Understanding Onychomycosis and Its Impact
Onychomycosis is a widespread issue, affecting around 5.5% of the global population. This condition is responsible for approximately 50% of all nail disorder appointments. Regarded as a persistent and hard-to-treat ailment, onychomycosis often poses challenges in achieving successful long-term treatment due to adherence issues. Efinaconazole's unique properties, particularly its high nail-penetrating capabilities and binding affinity to keratin, make it an effective topical treatment.
Enhancing the Dermatology Portfolio
The approval of efinaconazole in Europe complements Almirall's existing portfolio in medical dermatology, reinforcing the company’s dedication to improving the lives of those dealing with skin infections. Almirall strives to provide dermatologists and patients with innovative treatment options that create a significant impact.
Commitment from Almirall Leadership
Dr. Karl Ziegelbauer, Almirall's Executive VP of R&D and CSO, emphasized the company's mission: "At Almirall, we are committed to addressing the unmet needs of individuals with persistent skin conditions. The approval of efinaconazole signifies a substantial advancement in our onychomycosis treatment offerings, and we are eager to make this therapy available to dermatologists across Europe soon."
Strategic Partnerships and Future Prospects
In a significant development back in July 2021, Almirall entered a license and distribution agreement with Kaken. This agreement grants Almirall exclusive rights to develop and market efinaconazole in Europe, thereby solidifying their position in the dermatology market.
Global Recognition of Efinaconazole
The product has been available in Japan since 2014, where it is marketed under the trade name Clenafin. It has also seen a successful launch in the United States, Canada, Korea, Hong Kong, and Macau, under the Jublia brand, thanks to Kaken Pharmaceutical’s partners.
Looking Towards Regulatory Approval in Europe
The completion of the decentralized regulatory procedure represents a pivotal step towards acquiring national marketing authorizations across various European countries. Almirall is currently collaborating with national regulatory authorities, with marketing authorizations anticipated within the first half of the year 2025.
About Almirall and Its Vision
Almirall is a trailblazer in the field of medical dermatology, consistently working with leading scientists, healthcare professionals, and patients. The company’s mission is to transform patients' lives by bringing their aspirations for health to reality. With a focus on innovative and differentiated medical dermatology products, Almirall is dedicated to meeting the needs of patients worldwide.
Founded in 1944 and headquartered in Barcelona, Almirall is publicly listed on the Spanish Stock Exchange (ticker: ALM). The company reported total revenues of €898.8 million in 2023 and employs approximately 1,900 individuals globally. Almirall is committed to enhancing the quality of life for patients, offering solutions in over 100 countries.
Frequently Asked Questions
What is efinaconazole used to treat?
Efinaconazole is used to treat onychomycosis, a fungal infection of the nails.
When is efinaconazole expected to be available in Europe?
Marketing authorizations for efinaconazole are anticipated within the first half of 2025.
What are the unique properties of efinaconazole?
Efinaconazole has high nail-penetrating properties and a strong binding affinity to keratin, enhancing treatment efficacy.
What commitment does Almirall have towards dermatology?
Almirall is dedicated to medical dermatology and aims to provide innovative treatment options for those with skin conditions.
In how many countries does Almirall operate?
Almirall products are available in over 100 countries worldwide.
